Genetic polymorphisms as a risk factor for dyslipidemia in children

Abstract

Dyslipidemia is an important etiological factor for development of cardiovascular disease, which is the leading cause of deaths in adults. Given the growing global epidemic of dyslipidemia, lipoprotein metabolism disorders have become an important health problem not only in adulthood, but have also emerged as an increasingly risk factor in childhood. Although several genome-wide association studies in multiple large population-based cohorts of adults and meta-analyses have identified susceptibility genes or loci, especially in lipid-related traits, it is of great importance to evaluate genetic predisposition at an early age. Recent findings suggest that the identification of polymorphisms in the metabolism of lipids in childhood may help fight subclinical atherosclerosis and its progression to cardiovascular complications in adulthood. Therefore, the aim of this study was to review genetic polymorphisms as risk factors associated with dyslipidemia in children and adolescents.

Lack of Associations Between PAI-1 and FXIII Polymorphisms and Arterial Ischemic Stroke in Children: A Systematic Review and Meta-Analysis

“…Numerous polymorphic variants of genes encoding proteins involved in the coagulation cascade, lipidrelated traits, or homocysteine metabolism are suggested to be related to AIS, both in adults and children. [2][3][4][5][6][7] Polymorphisms within genes of plasminogen activator inhibitor (PAI-1) or coagulation factors FII, FV, FVII, and FXIII are at increasing interests. [2][3][4][5] The insertion/deletion (-675_-674insG) polymorphism is located in the promoter region of PAI-1 gene and was found to increase the risk of myocardial infarction and coronary artery disease (CAD).…”

Relationship of lipid regulatory gene polymorphisms and dyslipidemia in a pediatric population: the CASPIAN III study

“…Christie et al have demonstrated that lipid-lowering preventative strategies during childhood could be effective in genetically predisposed pediatric populations [9]. In addition, recent studies suggested that for the prevention of subclinical atherosclerosis and its progression to clinical cardiovascular disease (CVD) and related complications, identification of lipid metabolism-related polymorphisms in early life could be helpful [10].…”